Exicure, Inc. (XCUR): Shareholders' Equity
$3.93M
As of 2025-12-31
$977.0K
As of 2026-06-30
-35.9%
3-year compound annual growth
-42.3%
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $3.93M | -42.0% | 2026-03-25, Balance as of period end |
| 2024-12-31 | $6.77M | +123.4% | 2026-03-25, Balance as of period end |
| 2023-12-31 | $3.03M | -79.7% | 2025-03-18, Balance as of period end |
| 2022-12-31 | $14.92M | +32.9% | 2024-06-06, Balance as of period end |
| 2021-12-31 | $11.23M | -81.7% | 2023-03-27, Balance as of period end |
| 2020-12-31 | $61.51M | -23.8% | 2022-03-25, Balance as of period end |
| 2019-12-31 | $80.75M | +285.4% | 2021-03-11, Balance as of period end |
| 2018-12-31 | $20.95M | +4.9% | 2020-03-10, Balance as of period end |
| 2017-12-31 | $19.98M | n/c | 2019-09-23, Balance as of period end |
| 2016-12-31 | $2.45M | n/a | 2018-03-09, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Exicure, Inc. (XCUR) | 2025-12-31 | $3.93M | -42.0% |
| Abbott Laboratories (ABT) | 2025-12-31 | $52.13B | +9.4% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $18.47B | +13.1% |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | $26.88M | -1.8% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $26.54B | +85.9% |
| Pfizer Inc (PFE) | 2025-12-31 | $86.78B | -1.9% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $81.54B | +14.1% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $161.55M | +0.3% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $52.66B | +13.6% |
Compare XCUR, ABT, BMY, TXMD side by side · Screen every company in Pharmaceutical Preparations ↗